Better Evidence for Selecting Transplant Fluids

PHASE3CompletedINTERVENTIONAL
Enrollment

808

Participants

Timeline

Start Date

January 26, 2018

Primary Completion Date

July 29, 2021

Study Completion Date

May 3, 2022

Conditions
End Stage Kidney DiseaseDelayed Graft FunctionKidney Transplant; Complications
Interventions
DRUG

Plasma-Lyte 148 (approx. pH 7.4) IV Infusion

Plasma-Lyte 148 (approx. pH 7.4) IV Infusion is a sterile, clear, non-pyrogenic isotonic solution and when administered intravenously is a source of water, electrolytes and calories. Plasma-Lyte 148 intravenous infusion is indicated as a source of water \& electrolytes or as an alkalinising agent.

DRUG

0.9% SODIUM CHLORIDE 9g/L injection BP

Sodium chloride (0.9% saline) infusion is a sterile, non-pyrogenic solution of sodium chloride in Water for Injections. The concentration of sodium chloride is 154mmol/L. Sodium chloride (0.9%) intravenous infusion is indicated for extra-cellular fluid replacement and in the management of metabolic alkalosis in the presence of fluid loss, and for restoring or maintaining the concentration of sodium and chloride ions.

Trial Locations (18)

1142

Auckland City Hospital, Auckland

Starship Children's Hospital, Auckland

2031

Sydney Children's Hospital, Randwick

Prince of Wales Hospital, Sydney

2050

Royal Prince Alfred Hospital, Sydney

2145

The Children's Hospital at Westmead, Sydney

Westmead Hospital, Sydney

3065

St Vincent's Hospital (Melbourne) Ltd, Melbourne

3084

Austin Health, Melbourne

3168

Monash Children's Hospital, Melbourne

Monash Medical Centre, Melbourne

4101

Queensland Children's Hospital, Brisbane

4102

Princess Alexandra Hospital, Brisbane

5000

Royal Adelaide Hospital, Adelaide

6009

Sir Charles Gairdner Hospital, Perth

6021

Wellington Hospital, Wellington

6150

Fiona Stanley Hospital, Murdoch

8011

Christchurch Hospital, Christchurch

All Listed Sponsors
collaborator

Australian Government Department of Health and Ageing

OTHER_GOV

collaborator

Health Research Council, New Zealand

OTHER

collaborator

Baxter Healthcare Corporation

INDUSTRY

lead

The University of Queensland

OTHER

NCT03829488 - Better Evidence for Selecting Transplant Fluids | Biotech Hunter | Biotech Hunter